Literature DB >> 9694543

Serum antioxidant status and oxidized LDL in well-controlled young type 1 diabetic patients with and without subclinical complications.

D Willems1, H Dorchy, D Dufrasne.   

Abstract

It has been suggested that oxidative stress may play an important role in the pathogenesis of diabetic complications because hyperglycemia may cause increased production of free radicals. However, studies on the antioxidant status of young type 1 diabetic patients are very scarce as well as the relationships of oxidative stress and the presence of subclinical complications. Therefore, it was decided to evaluate autoantibodies against LDL (o-LAB) and antioxidant status in relationship with glycated hemoglobin levels (HbA1c), lipoproteins and subclinical complications (retinopathy, neuropathy and nephropathy). The study included 110 young type 1 diabetic patients, with a median age of 15 years and a median diabetes duration of 5 years. The mean+/-S.E.M. of HbA1c levels was 7.1+/-0.2%. Subclinical complications were detected in 26 patients. Total antioxidant status (TAS), vitamin A or E were not decreased in the patients and no significant differences were noted between the different subgroups of patients classified according to their subclinical complications. HbA1c levels were not related to antioxidants. Autoantibodies against LDL-lipoproteins decreased with age and diabetes duration, as reported in healthy non diabetic subjects. In conclusion, in the diabetic patients with a more or less good diabetic control, increased lipid peroxidation or reduced lipid antioxidant defense could not be demonstrated, even for the patients with subclinical complications.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9694543     DOI: 10.1016/s0021-9150(97)00320-1

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  8 in total

Review 1.  Hyperlipidemia: a new therapeutic target for diabetic neuropathy.

Authors:  Andrea M Vincent; Lucy M Hinder; Rodica Pop-Busui; Eva L Feldman
Journal:  J Peripher Nerv Syst       Date:  2009-12       Impact factor: 3.494

Review 2.  New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism.

Authors:  Stephanie Eid; Kelli M Sas; Steven F Abcouwer; Eva L Feldman; Thomas W Gardner; Subramaniam Pennathur; Patrice E Fort
Journal:  Diabetologia       Date:  2019-07-25       Impact factor: 10.122

3.  Erythrocyte oxidant/antioxidant status of diabetic patients.

Authors:  S Büyükkoçak; H S Oztürk; M N Tamer; M Kaçmaz; M Y Cimen; I Durak
Journal:  J Endocrinol Invest       Date:  2000-04       Impact factor: 4.256

4.  Effects of N1-methylnicotinamide on oxidative and glycooxidative stress markers in rats with streptozotocin-induced diabetes mellitus.

Authors:  Zuzana Országhová; Ol'ga Uličná; Anna Liptáková; Ingrid Zitňanová; Jana Muchová; Cezary Watala; Zdeňka Duračková
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

5.  Association of postprandial hyperglycemia with in vitro LDL oxidation in non-smoking patients with type 1 diabetes--a cross-sectional study.

Authors:  Simone H de Castro; Hugo C Castro-Faria-Neto; Marilia B Gomes
Journal:  Rev Diabet Stud       Date:  2005-11-10

6.  Role of nitrosative and oxidative stress in neuropathy in patients with type 2 diabetes mellitus.

Authors:  Marwan S Al-Nimer; Fakhir S Al-Ani; Fatima S Ali
Journal:  J Neurosci Rural Pract       Date:  2012-01

7.  Elevated Levels of Plasma IgA Autoantibodies against Oxidized LDL Found in Proliferative Diabetic Retinopathy but Not in Nonproliferative Retinopathy.

Authors:  Satu Vavuli; Tuire Salonurmi; Sirpa Loukovaara; Antti E Nissinen; Markku J Savolainen; M Johanna Liinamaa
Journal:  J Diabetes Res       Date:  2016-12-20       Impact factor: 4.011

8.  Changes in oxidant-antioxidant status in young diabetic patients from clinical onset onwards.

Authors:  P Martín-Gallán; A Carrascosa; M Gussinyé; C Domínguez
Journal:  J Cell Mol Med       Date:  2007 Nov-Dec       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.